Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bod Science's Enterprise Value for the quarter that ended in Jun. 2025 was A$4.76 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bod Science's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was A$0.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bod Science EV-to-EBIT Related Terms
Bod Science EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bod Science's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bod Science's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bod Science EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bod Science's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bod Science's EV-to-EBIT falls into.
Bod Science's current Enterprise Value is A$3.19 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bod Science's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was A$0.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bod Science (ASX:BOD) has a EV-to-EBIT of 12.31 as of Jul. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bod Science and its competitors.
Is Bod Science's EV-to-EBIT too high?
Bod Science's current EV-to-EBIT is 12.31. The Drug Manufacturers industry median EV-to-EBIT is 15.73. Bod Science's value of 12.31 is 21.7% below this industry median. Overall, Bod Science has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bod Science's EV-to-EBIT compare to ZTS?
Bod Science's EV-to-EBIT of 12.31 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBIT is 15.73. Bod Science's value of 12.31 is 21.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.73, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bod Science's current EV-to-EBIT of 12.31 is 21.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bod Science and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bod Science's current EV-to-EBIT is 12.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bod Science stock overvalued right now?
Bod Science (ASX:BOD) has a current EV-to-EBIT of 12.31. The stock's GF Value™ is A$0.04, compared to a current price of A$0.02 — trading 40% below its estimated fair value. The current EV-to-EBIT is 12.31 and 21.7% below the Drug Manufacturers industry median of 15.73. Bod Science's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bod Science (ASX:BOD), the current EV-to-EBIT is 12.31 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bod Science (ASX:BOD) Overvalued in 2026?
Based on GuruFocus' analysis, Bod Science stock appears to be undervalued.
The current stock price of A$0.02 is trading 40% below its estimated GF Value™ of A$0.04.
Key valuation signals for ASX:BOD:
EV-to-EBIT: 12.31
GF Value™: A$0.04 vs. price of A$0.02 (40% below fair value)
Industry Position: 21.7% below the Drug Manufacturers median
No single metric tells the full story. See the ASX:BOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bod Science Ltd is a healthcare company combining the power of nature and science to deliver cannabis-derived health and skincare products, designed to improve lives and transform the medicinal cannabis, CBD, and hemp market. The firm is focused on cannabis drug development and products. The company is focused on progressing Research and Development and a defined clinical trial pathway to commercialize and deliver premium, scientifically trusted products for the consumer and medical markets. It earned it profits and sales revenue from Australia even though have segment in UK, Europe and USA.
12GF Score
Get the complete analysis for ASX:BOD
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BOD has been successfully added to your 
